Janel Long-Boyle, PharmD, PhD

Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
AddressLocation Required, #001
Phone415-640-1569
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. J Pharmacokinet Pharmacodyn. 2024 Mar 23. Hughes JH, Long-Boyle J, Keizer RJ. PMID: 38520573.
      View in: PubMed   Mentions:    Fields:    
    2. Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Children (Basel). 2023 Oct 25; 10(11). Mike JK, White Y, Hutchings RS, Vento C, Ha J, Iranmahboub A, Manzoor H, Gunewardena A, Cheah C, Wang A, Goudy BD, Lakshminrusimha S, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E. PMID: 38002819; PMCID: PMC10670092.
      View in: PubMed   Mentions:
    3. Busulfan and subsequent malignancy: An evidence-based risk assessment. Pediatr Blood Cancer. 2024 Jan; 71(1):e30738. Long-Boyle JR, Kohn DB, Shah AJ, Spencer SM, Sevilla J, Booth C, López Lorenzo JL, Nicoletti E, Shah A, Reatz M, Matos J, Schwartz JD. PMID: 37856098.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Perinatal Azithromycin Provides Limited Neuroprotection in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Stroke. 2023 11; 54(11):2864-2874. Mike JK, White Y, Hutchings RS, Vento C, Ha J, Manzoor H, Lee D, Losser C, Arellano K, Vanhatalo O, Seifert E, Gunewardena A, Wen B, Wang L, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Wu YW, Fineman JR, Ferriero DM, Maltepe E. PMID: 37846563; PMCID: PMC10589434.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    5. Lentiviral Gene Therapy for Artemis-Deficient SCID. N Engl J Med. 2022 12 22; 387(25):2344-2355. Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, Dara J, Long-Boyle J, Oh J, Chan W, Chag S, Broderick L, Chellapandian D, Decaluwe H, Golski C, Hu D, Kuo CY, Miller HK, Petrovic A, Currier R, Hilton JF, Punwani D, Dvorak CC, Malech HL, McIvor RS, Puck JM. PMID: 36546626; PMCID: PMC9884487.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    6. Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation. Pharmaceutics. 2022 Nov 15; 14(11). Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, Long S, Gupta AO, Horn B, Lamba JK, Huang L, Apsel-Winger B, Keizer RJ, Savic R, Long-Boyle J. PMID: 36432661.
      View in: PubMed   Mentions:
    7. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. J Chromatogr Open. 2022 Nov; 2. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. PMID: 35875822; PMCID: PMC9302610.
      View in: PubMed   Mentions:
    8. Defining Longer-Term Outcomes in an Ovine Model of Moderate Perinatal Hypoxia-Ischemia. Dev Neurosci. 2022; 44(4-5):277-294. Mike JK, Wu KY, White Y, Pathipati P, Ndjamen B, Hutchings RS, Losser C, Vento C, Arellano K, Vanhatalo O, Ostrin S, Windsor C, Ha J, Alhassen Z, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Chen P, Wu YW, Fineman JR, Ferriero DM, Maltepe E. PMID: 35588703; PMCID: PMC9474697.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    9. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. J Clin Pharmacol. 2022 07; 62(7):873-882. Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Apsel Winger B. PMID: 35048362.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 04; 28(4):196-202. Bognàr T, Bartelink IH, Egberts TCG, Rademaker CMA, Versluys AB, Slatter MA, Kletzel M, Nath CE, Cuvelier GDE, Savic RM, Dvorak C, Long-Boyle JR, Cowan MJ, Bittencourt H, Bredius RGM, Güngör T, Shaw PJ, Ansari M, Hassan M, Krajinovic M, Hempel G, Marktel S, Chiesa R, Théoret Y, Lund T, Orchard PJ, Wynn RF, Boelens JJ, Lalmohamed A. PMID: 35065280.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    11. Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation. Front Pharmacol. 2021; 12:750672. Brooks JT, Keizer RJ, Long-Boyle JR, Kharbanda S, Dvorak CC, Friend BD. PMID: 34950026; PMCID: PMC8689075.
      View in: PubMed   Mentions: 3  
    12. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis. Transplant Cell Ther. 2022 02; 28(2):104.e1-104.e7. Takahashi T, Illamola SM, Jennissen CA, Long SE, Lund TC, Orchard PJ, Gupta AO, Long-Boyle JR. PMID: 34883294.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood Adv. 2021 10 12; 5(19):3900-3912. Bankova AK, Pang WW, Velasco BJ, Long-Boyle JR, Shizuru JA. PMID: 34448832; PMCID: PMC8679673.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    14. A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults. Front Pediatr. 2021; 9:713091. Apsel Winger B, Long SE, Brooks J, Gupta AO, Dvorak CC, Long-Boyle JR. PMID: 34350148; PMCID: PMC8326409.
      View in: PubMed   Mentions: 1  
    15. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv. 2021 04 27; 5(8):2106-2114. Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. PMID: 33877298; PMCID: PMC8095147.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transplant Cell Ther. 2021 03; 27(3):258.e1-258.e6. Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, Dvorak CC, Long-Boyle J. PMID: 33781528.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411. Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL, IGNITE Pharmacogenetics Working Group. PMID: 33315113; PMCID: PMC7737091.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    18. Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients. Int J Mol Sci. 2020 Aug 06; 21(16). Shukla P, Dvorak CC, Long-Boyle J, Kharbanda S. PMID: 32781600; PMCID: PMC7460609.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Front Pharmacol. 2020; 11:888. Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J. PMID: 32714184; PMCID: PMC7351521.
      View in: PubMed   Mentions: 14  
    20. Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants. Biol Blood Marrow Transplant. 2020 09; 26(9):1646-1654. Contreras CF, Long-Boyle JR, Shimano KA, Melton A, Kharbanda S, Dara J, Higham C, Huang JN, Cowan MJ, Dvorak CC. PMID: 32534101.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    21. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. J Clin Pharmacol. 2020 09; 60(9):1209-1219. Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. PMID: 32476174.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    22. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020 May 26; 11(21):1942-1952. Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M. PMID: 32523649; PMCID: PMC7260122.
      View in: PubMed   Mentions: 30     Fields:    
    23. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019 04 18; 380(16):1525-1534. Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. PMID: 30995372; PMCID: PMC6636624.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCellsCTClinical Trials
    24. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1603-1610. Wang H, Jones AK, Dvorak CC, Huang L, Orchard P, Ivaturi V, Long-Boyle J. PMID: 31002993; PMCID: PMC10291704.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    25. Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. Biol Blood Marrow Transplant. 2019 07; 25(7):1355-1362. Dvorak CC, Long-Boyle J, Dara J, Melton A, Shimano KA, Huang JN, Puck JM, Dorsey MJ, Facchino J, Chang CK, Cowan MJ. PMID: 30876930; PMCID: PMC7384257.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    26. Determination of melphalan in human plasma by UPLC-UV method. Cancer Chemother Pharmacol. 2019 05; 83(5):905-910. Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J. PMID: 30847504; PMCID: PMC6490959.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS Biol. 2019 Jan; 17(1):e3000119. Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, Krtolica A, Maltepe E. PMID: 30677022; PMCID: PMC6345423.
      View in: PubMed   Mentions: 1     Fields:    
    28. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. J Am Coll Clin Pharm. 2019 Jun; 2(3):214-221. Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B. PMID: 32391517; PMCID: PMC7207007.
      View in: PubMed   Mentions: 5  
    29. Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS Biol. 2018 10; 16(10):e2005924. Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, Krtolica A, Maltepe E. PMID: 30335746; PMCID: PMC6193608.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    30. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants. Int J Pediatr Otorhinolaryngol. 2018 Feb; 105:48-51. Czechowicz JA, Long-Boyle JR, Rosbe KW, Mathes EF, Frieden IJ, Shimano KA. PMID: 29447818.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    31. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J. 2017 09; 50(3). Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long-Boyle J, Hedlin H, Zamanian RT. PMID: 28893866.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    32. Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. Hematol Oncol Clin North Am. 2017 10; 31(5):809-822. Cowan MJ, Dvorak CC, Long-Boyle J. PMID: 28895849.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    33. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1701-1713. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. PMID: 28684371; PMCID: PMC6108324.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    34. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017 Apr 04; 8(14):23851-23861. Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG. PMID: 27793021; PMCID: PMC5410349.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    35. Busulfan after HSCT in children and young adults - Authors' reply. Lancet Haematol. 2017 03; 4(3):e103-e104. Bartelink IH, Lalmohamed A, Long-Boyle JR, Boelens JJ. PMID: 28257750.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. PMID: 27746112; PMCID: PMC5159247.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    37. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet. 2016 May; 55(5):551-93. McCune JS, Bemer MJ, Long-Boyle J. PMID: 26620047; PMCID: PMC4824644.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    38. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Transl Res. 2016 09; 175:103-115.e4. Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA. PMID: 27094990; PMCID: PMC5003687.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    39. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Jul 15; 192(2):254-7. Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT. PMID: 26177174; PMCID: PMC4532822.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    40. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015 Apr; 37(2):236-45. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. PMID: 25162216; PMCID: PMC4342323.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    41. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics. Drug Metab Lett. 2015; 9(2):80-7. Miyagi SJ, Long-Boyle JR. PMID: 26031462.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 01; 960:194-9. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. PMID: 24820973; PMCID: PMC4110960.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    43. Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan. Ther Drug Monit. 2014 Apr; 36(2):169-74. French D, Sujishi KK, Long-Boyle JR, Ritchie JC. PMID: 24625541.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    44. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014 Feb; 133(2):335-47. Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC, workshop participants. PMID: 24139498; PMCID: PMC3960312.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    45. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1608-14. Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J. PMID: 24029650; PMCID: PMC3848313.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    46. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal. 2013 Dec; 86:198-203. Huang L, Lizak P, Aweeka F, Long-Boyle J. PMID: 24013121; PMCID: PMC3835489.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    47. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013 Feb; 75(2):463-75. Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. PMID: 22765258; PMCID: PMC3579261.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    48. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1656-63. Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B. PMID: 22609040.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    49. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J Clin Pharmacol. 2012 Nov; 52(11):1665-75. Kim H, Long-Boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR, Jacobson P, Brundage R. PMID: 22110162.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    50. Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. J Clin Pharmacol. 2011 May; 51(5):679-86. Long-Boyle J, Huang J, Rydholm N, Smith A, Orchard P, Tolar J, Jacobson P. PMID: 20525919.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    51. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2011 Jan; 46(1):20-6. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA. PMID: 20383215; PMCID: PMC2904846.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    52. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Jul; 44(2):113-20. Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, DeFor T, Jennissen C, Brunstein C, Wagner J, Tomblyn M, Weisdorf D. PMID: 19151792; PMCID: PMC3204943.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    53. High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction. Biol Blood Marrow Transplant. 2005 Dec; 11(12):977-8. Jacobson P, Long J, Rogosheske J, Brunstein C, Weisdorf D. PMID: 16338619.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005 Nov; 78(5):486-500. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, Tan Y, Long J, Remmel R, Sawchuk R, McGlave P. PMID: 16321615.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    55. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003 Jul 01; 102(1):146-51. Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR. PMID: 12609838.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Janel's Networks
    Concepts (229)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (50)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.